vs

Side-by-side financial comparison of Journey Medical Corp (DERM) and HEALTHY CHOICE WELLNESS CORP. (HCWC). Click either name above to swap in a different company.

HEALTHY CHOICE WELLNESS CORP. is the larger business by last-quarter revenue ($18.7M vs $16.1M, roughly 1.2× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -8.9%, a 1.1% gap on every dollar of revenue.

Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.

DERM vs HCWC — Head-to-Head

Bigger by revenue
HCWC
HCWC
1.2× larger
HCWC
$18.7M
$16.1M
DERM
Higher net margin
DERM
DERM
1.1% more per $
DERM
-7.8%
-8.9%
HCWC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DERM
DERM
HCWC
HCWC
Revenue
$16.1M
$18.7M
Net Profit
$-1.2M
$-1.7M
Gross Margin
39.1%
Operating Margin
-2.8%
-7.6%
Net Margin
-7.8%
-8.9%
Revenue YoY
27.3%
Net Profit YoY
-182.0%
EPS (diluted)
$-0.04
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DERM
DERM
HCWC
HCWC
Q4 25
$16.1M
$18.7M
Q3 25
$17.0M
$19.0M
Q2 25
$15.0M
$20.2M
Q1 25
$13.1M
$20.3M
Q4 24
$12.6M
Q3 24
$14.6M
$18.2M
Q2 24
$14.9M
Q1 24
$13.0M
Net Profit
DERM
DERM
HCWC
HCWC
Q4 25
$-1.2M
$-1.7M
Q3 25
$-2.3M
$-1.2M
Q2 25
$-3.8M
$-339.4K
Q1 25
$-4.1M
$-712.4K
Q4 24
$1.5M
Q3 24
$-2.4M
$-2.7M
Q2 24
$-3.4M
Q1 24
$-10.4M
Gross Margin
DERM
DERM
HCWC
HCWC
Q4 25
39.1%
Q3 25
38.8%
Q2 25
40.1%
Q1 25
38.8%
Q4 24
82.3%
Q3 24
63.9%
38.4%
Q2 24
56.0%
Q1 24
47.7%
Operating Margin
DERM
DERM
HCWC
HCWC
Q4 25
-2.8%
-7.6%
Q3 25
-9.0%
-3.2%
Q2 25
-19.2%
-0.2%
Q1 25
-25.3%
-2.0%
Q4 24
17.7%
Q3 24
-19.8%
-2.0%
Q2 24
-19.7%
Q1 24
-77.4%
Net Margin
DERM
DERM
HCWC
HCWC
Q4 25
-7.8%
-8.9%
Q3 25
-13.6%
-6.4%
Q2 25
-25.3%
-1.7%
Q1 25
-31.0%
-3.5%
Q4 24
12.1%
Q3 24
-16.3%
-14.6%
Q2 24
-22.6%
Q1 24
-80.1%
EPS (diluted)
DERM
DERM
HCWC
HCWC
Q4 25
$-0.04
$-0.05
Q3 25
$-0.09
$-0.09
Q2 25
$-0.16
$-0.03
Q1 25
$-0.18
$-0.07
Q4 24
$0.10
Q3 24
$-0.12
$-0.29
Q2 24
$-0.17
Q1 24
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DERM
DERM
HCWC
HCWC
Cash + ST InvestmentsLiquidity on hand
$24.1M
$3.0M
Total DebtLower is stronger
$25.3M
$7.3M
Stockholders' EquityBook value
$31.9M
$7.3M
Total Assets
$94.6M
$33.5M
Debt / EquityLower = less leverage
0.79×
1.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DERM
DERM
HCWC
HCWC
Q4 25
$24.1M
$3.0M
Q3 25
$24.9M
$3.0M
Q2 25
$20.3M
$4.7M
Q1 25
$21.1M
$1.8M
Q4 24
$20.3M
Q3 24
$22.5M
$1.8M
Q2 24
$23.9M
Q1 24
$24.1M
Total Debt
DERM
DERM
HCWC
HCWC
Q4 25
$25.3M
$7.3M
Q3 25
$25.2M
$8.5M
Q2 25
$25.1M
$9.7M
Q1 25
$25.0M
$10.6M
Q4 24
$24.9M
Q3 24
$19.8M
$11.6M
Q2 24
$19.7M
Q1 24
$14.7M
Stockholders' Equity
DERM
DERM
HCWC
HCWC
Q4 25
$31.9M
$7.3M
Q3 25
$25.9M
$5.9M
Q2 25
$19.2M
$5.8M
Q1 25
$21.5M
$2.1M
Q4 24
$20.1M
Q3 24
$10.9M
$2.9M
Q2 24
$11.3M
Q1 24
$13.0M
Total Assets
DERM
DERM
HCWC
HCWC
Q4 25
$94.6M
$33.5M
Q3 25
$85.2M
$33.7M
Q2 25
$81.2M
$36.4M
Q1 25
$85.0M
$34.1M
Q4 24
$80.2M
Q3 24
$64.0M
$33.2M
Q2 24
$65.2M
Q1 24
$66.6M
Debt / Equity
DERM
DERM
HCWC
HCWC
Q4 25
0.79×
1.00×
Q3 25
0.97×
1.43×
Q2 25
1.30×
1.69×
Q1 25
1.16×
5.01×
Q4 24
1.24×
Q3 24
1.81×
3.95×
Q2 24
1.75×
Q1 24
1.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DERM
DERM
HCWC
HCWC
Operating Cash FlowLast quarter
$-6.3M
$-855.1K
Free Cash FlowOCF − Capex
$-927.1K
FCF MarginFCF / Revenue
-5.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$675.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DERM
DERM
HCWC
HCWC
Q4 25
$-6.3M
$-855.1K
Q3 25
$-2.4M
$-308.7K
Q2 25
$-942.0K
$1.1M
Q1 25
$-2.8M
$1.1M
Q4 24
$2.2M
Q3 24
$-1.2M
Q2 24
$-5.2M
Q1 24
$-5.0M
Free Cash Flow
DERM
DERM
HCWC
HCWC
Q4 25
$-927.1K
Q3 25
$-351.3K
Q2 25
$988.6K
Q1 25
$965.3K
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
DERM
DERM
HCWC
HCWC
Q4 25
-5.0%
Q3 25
-1.8%
Q2 25
4.9%
Q1 25
4.8%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
DERM
DERM
HCWC
HCWC
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.4%
Q1 25
0.6%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
DERM
DERM
HCWC
HCWC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.46×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DERM
DERM

Qbrexza$5.5M35%
Emrosi$5.0M31%
Accutane$3.1M19%
Other$2.5M15%

HCWC
HCWC

Retail Grocery$17.1M91%
Food Service Restaurant$1.7M9%

Related Comparisons